Advertisement
Advertisement
February 8, 2015
Boston Scientific to Distribute Bard's Lutonix Drug-Coated Balloon in the US
February 9, 2015—Boston Scientific Corporation and C.R. Bard, Inc. have announced an agreement whereby Boston Scientific gains the ability to distribute the Lutonix 035 drug-coated balloon (DCB) in the United States. The DCB will continue to be distributed by Bard as well.
The Lutonix platform, which was acquired by Bard in 2011, was the first DCB to gain US Food and Drug Administration approval. The DCB is approved for use in diseased femoropopliteal arteries. The Medtronic In.Pact Admiral has since also been approved in the United States.
Terms of the agreement were not disclosed.
Executives from both companies commented on the agreement in the announcement:
"Drug-coated balloons are a growing part of the treatment algorithm for peripheral artery disease and provide an alternative in the event a physician chooses not to place a permanent implant or scaffold," said Jeff Mirviss, who is President, Peripheral Interventions, at Boston Scientific. "We believe Bard's Lutonix DCB is a great addition to our broad portfolio of vascular products."
"This agreement is designed to expand the reach of the Lutonix DCB and will afford more patients suffering from peripheral artery disease an opportunity to benefit from this innovative technology and clinically proven therapy," said Steve Williamson, President of Bard Peripheral Vascular.
Advertisement
Advertisement
